Hiroshi Shiku

21.7k total citations · 1 hit paper
535 papers, 16.3k citations indexed

About

Hiroshi Shiku is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Hiroshi Shiku has authored 535 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Immunology, 194 papers in Molecular Biology and 158 papers in Oncology. Recurrent topics in Hiroshi Shiku's work include Immunotherapy and Immune Responses (124 papers), CAR-T cell therapy research (82 papers) and Immune Cell Function and Interaction (77 papers). Hiroshi Shiku is often cited by papers focused on Immunotherapy and Immune Responses (124 papers), CAR-T cell therapy research (82 papers) and Immune Cell Function and Interaction (77 papers). Hiroshi Shiku collaborates with scholars based in Japan, United States and Germany. Hiroshi Shiku's co-authors include Lloyd J. Old, Herbert F. Oettgen, Koichi Furukawa, Hideo Wada, Hiroaki Ikeda, Kazunari Akiyoshi, Takashi Takahashi, Takeshi Urano, Eiichi Nakayama and Naozumi Harada and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Hiroshi Shiku

522 papers receiving 15.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineering hybrid exosomes by membrane fusion with liposomes

2016 605 citations Naozumi Harada, Hiroshi Shiku et al. profile →

Peers

Countries citing papers authored by Hiroshi Shiku

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Shiku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Shiku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Shiku more than expected).

Fields of papers citing papers by Hiroshi Shiku

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Shiku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Shiku. The network helps show where Hiroshi Shiku may publish in the future.

Co-authorship network of co-authors of Hiroshi Shiku

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Shiku. A scholar is included among the top collaborators of Hiroshi Shiku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Shiku. Hiroshi Shiku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model 2024 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), Julia Lopatnikova, (unknown), (unknown), (unknown), (unknown), E. L. Zavjalov, (unknown), Hiroshi Shiku, (unknown), С. В. Сенников	3
2	Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model 2023 ·Biomedicine & Pharmacotherapy ·(unknown), (unknown), Katsunori Sasaki, Osamu Sato, Takahiro Tsuchikawa, Linan Wang, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, Yoshifumi Hirokawa, Kanako C. Hatanaka, Yutaka Hatanaka, (unknown), Hiroshi Shiku, Satoshi Hirano	5
3	Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Julia Lopatnikova, (unknown), (unknown), E. L. Zavjalov, (unknown), Yasushi Akahori, Hiroshi Shiku, (unknown), С. В. Сенников	6
4	Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells 2023 ·Cancers ·Osamu Sato, Takahiro Tsuchikawa, Takuma Kato, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, (unknown), Katsunori Sasaki, Toru Nakamura, (unknown), Tomohiro Suzuki, Linan Wang, (unknown), Kanako C. Hatanaka, Tomoko Mitsuhashi, Yutaka Hatanaka, Hiroshi Shiku, Satoshi Hirano	11
5	Phenotype and effector functions of GD2-specific CAR-T lymphocytes in vitro 2022 ·Immunologiya ·(unknown), (unknown), (unknown), Valeriy Tereshchenko, (unknown), (unknown), (unknown), (unknown), Hiroshi Shiku, С. В. Сенников	2
6	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma 2022 ·Biomedicines ·Wenjie Gong, Lei Wang, Maria‐Luisa Schubert, Christian Kleist, Brigitte Neuber, Sanmei Wang, Mingya Yang, Angela Hückelhoven‐Krauss, Depei Wu, Anita Schmitt, Carsten Müller‐Tidow, Hiroshi Shiku, Michael Schmitt, Leopold Sellner	4
7	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance 2019 ·Journal of Clinical Investigation ·Daisuke Muraoka, Naohiro Seo, Tae Hayashi, Yoshiro Tahara, Keisuke Fujii, Isao Tawara, Yoshihiro Miyahara, (unknown), Hideo Yagita∥, Seiya Imoto, Rui Yamaguchi, Mitsuhiro Komura, Satoru Miyano, Masahiro Goto, Shin‐ichi Sawada, Akira Asai, Hiroaki Ikeda, Kazunari Akiyoshi, Naozumi Harada, Hiroshi Shiku	117
8	Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia 2016 ·Clinical Cancer Research ·Hiroki Tanaka, Hiroshi Fujiwara, Fumihiro Ochi, Kazushi Tanimoto, (unknown), Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Takashi Sugiyama, A. John Barrett, Masaki Yasukawa	20
9	Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy 2014 ·Cancer Immunology Research ·Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai, (unknown), Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, J. Carl Barrett, Eiichi Ishii, Masaki Yasukawa	34
10	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals 2010 ·Clinical Cancer Research ·(unknown), Hiroyoshi Nishikawa, Daisuke Muraoka, Linan Wang, Takuro Noguchi, Eiichi Sato, Satoshi Kondo, James P. Allison, Shimon Sakaguchi, Lloyd J. Old, Takuma Kato, Hiroshi Shiku	106
11	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR 2009 ·Cancer Research ·Sachiko Okamoto, Junichi Mineno, Hiroaki Ikeda, Hiroshi Fujiwara, Masaki Yasukawa, Hiroshi Shiku, Ikunoshin Kato	143
12	Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling 2008 ·Cancer Research ·Hiroyoshi Nishikawa, Takuma Kato, (unknown), Yuki Orito, Eiichi Sato, Naozumi Harada, Sacha Gnjatic, Lloyd J. Old, Hiroshi Shiku	66
13	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis 2004 ·American Journal of Hematology ·(unknown), Hideo Wada, (unknown), Yuko Sakurai, Akane Sakaguchi, (unknown), Yasunori Abe, Takahiro Nakasaki, T Tsukada, Hiroshi Shiku, Tsutomu Nobori	7
14	Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity 2001 ·Proceedings of the National Academy of Sciences ·Hiroyoshi Nishikawa, (unknown), Hiroaki Ikeda, Miho Sakakura, Yoshihiro Miyahara, (unknown), Katsumi Mukai, Masato Watanabe, Kagemasa Kuribayashi, Lloyd J. Old, Hiroshi Shiku	62
15	HTLV-1 unrelated adult T-cell leukemia/lymphoma with unique phenotype and karyotype 2000 ·American Journal of Hematology ·Kazunori Nakase, Masaki Hasegawa, (unknown), Takeshi Ikeda, Shigehisa Tamaki, Motoaki Tanigawa, (unknown), Hiroshi Shiku	1
16	Effects of cyclosporin A on refractory B-cell chronic lymphocytic leukemia. 2000 ·PubMed ·(unknown), (unknown), Hiroshi Mitani, Takeshi Matsumoto, Hiroshi Miwa, K Kita, Hiroshi Shiku	3
17	Granulocyte colony-stimulating factor and its receptor in acute promyelocytic leukemia 1998 ·American Journal of Hematology ·Naoyuki Katayama, Kenkichi Kita, Keiki Kawakami, (unknown), Takayuki Sugawara, (unknown), Akihito Yonezawa, Kazuhiro Nishii, Hiroshi Miwa, Hideo Wada, Nobuyuki Minami, Hiroshi Shiku	13
18	Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries 1998 ·American Journal of Hematology ·Hideo Wada, Yoshitaka Mori, Minori Shimura, (unknown), (unknown), Takahiro Nakasaki, Masakatsu Nishikawa, Masahiko Nakano, Kousuke Kumeda, Toshihiro Kaneko, Shin Nakamura, Hiroshi Shiku	3
19	Granulocyte colony‐stimulating factor and its receptor in acute promyelocytic leukemia 1998 ·American Journal of Hematology ·Naoyuki Katayama, Kenkichi Kita, Keiki Kawakami, (unknown), Takayuki Sugawara, (unknown), Akihito Yonezawa, Kazuhiro Nishii, Hiroshi Miwa, Hideo Wada, Nobuyuki Minami, Hiroshi Shiku	2
20	erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. 1994 ·PubMed ·Koichi Motojima, (unknown), (unknown), Kunihide Izawa, Takashi Kanematsu, Hiroshi Shiku	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact